NHS logo Cellular Therapies Facility


Cellular Therapies FacilityThe Newcastle Biomedicine Cellular Therapies Facility (NBCTF) is a state-of-the-art clean room GMP service providing a dedicated home for the development of Advanced Therapeutic Medicinal Products (ATMPs), regenerative medicine therapies for use in clinical trials, tissue preparation for transplant and for the development of human Embryonic Stem Cells (hESCs).

Services Offered

Clinical Research Platform logoThe facility works to a Pharmaceutical Quality Management System (PQMS) designed to meet the requirements of the UK’s primary competent bodies. These are the Human Fertilisation and Embryology Authority (HFEA), Human Tissue Authority (HTA– this license is required in the UK in order to be able to handle, store and minimally manipulate cells and human tissues) and Medicines and Healthcare Products Regulatory Agency (MHRA).

The facility is joined up with the Stem cell laboratory in Haematological Sciences, Institute of Cellular Medicine, to form the joint (NBCTF). This facility has over 15 years experience of working with haematopoeitic stem cells, including Miltenyi Clinimacs isolation and T-cell depletion techniques. Professor Anne Dickinson is the director of the facility and brings with her over 25 years of experience in the manipulation of haematopoietic stem cells for clinical use.

The facility consists of 9 EU GMP ‘Grade B’ clean rooms, supported by 2 ‘Grade C’ preparation rooms, making the provision one of the largest academic run units in Europe. ‘Grade A’ working environments are provided for all cell manipulation activities; together with comprehensive incubation, centrifugation and storage facilities.

A Qualified Person (QP) is also available to ensure standards are met. The clean area and associated incubators and storage facilities are monitored 24 hours a day, 7 days a week. This means that every client can be confident that all work carried out in the facility is performed to the highest of standards and to the requirements of current regulatory authorities.

Further information: